What is the TB-500 Fragment 17-23?

It is the short LKKTETQ actin-binding region of Thymosin Beta-4, the segment thought to be primarily responsible for promoting cell migration, angiogenesis, and tissue repair.

Why pair it with BPC-157?

BPC-157 contributes angiogenic and growth-factor-driven repair while the TB-4 fragment contributes actin-based cell migration, so the blend targets complementary stages of healing.

Is this blend FDA-approved?

No. It is sold as a research chemical, and supporting data are preclinical and component-level rather than from approved clinical use.

← All peptides

Healing & Recovery

Research Chemical

BPC-157 Acetate / TB-500 Fragment 17-23 Blend

Also known as: BPC-157 Acetate + TB-500 Fragment 17-23 Blend

A research blend pairing the cytoprotective peptide BPC-157 with the actin-binding fragment 17-23 of Thymosin Beta-4 (TB-500). It is studied for soft-tissue repair, angiogenesis, and recovery.

Mechanism of Action

BPC-157 accelerates healing by upregulating VEGFR2-driven angiogenesis, activating the nitric oxide system, and enhancing fibroblast migration and growth-factor receptor expression in tendon, muscle, and gut tissue. The TB-500 fragment 17-23 contains the LKKTETQ actin-binding motif of Thymosin Beta-4, the active region responsible for promoting actin polymerization, cell migration, and angiogenesis while reducing inflammation. Delivering this short fragment focuses activity on the cytoskeletal-remodeling component of the parent peptide. The two agents target distinct but complementary phases of tissue regeneration.

Half-life: Short for BPC-157 (minutes to a few hours); the short TB-4 fragment is cleared rapidly on a similar timescale.
Administration Routes: subcutaneous
Research Status: Research Chemical